CVM Stock: CEL-SCI Corporation Stock Price, Analysis & Insights
Get live cvm stock price $5.85, comprehensive CEL-SCI Corporation stock analysis, charts, news, and expert forecast. Real-time cvm stock data and investment insights.
Loading chart...
Company Overview
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Company Information
- CEO
- Geert R. Kersten
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 43
Contact Information
- Website
- https://cel-sci.com
- Address
- 8229 Boone Boulevard
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.51) may provide portfolio stability
Business Model & Strategy
CEL-SCI Corporation operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Geert R. Kersten, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
CEL-SCI Corporation competes in the Biotechnology within the broader Healthcare. With 40.2 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange Arca, CEL-SCI Corporation provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating CEL-SCI Corporation should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for CEL-SCI Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for CEL-SCI Corporation
- ⚠Investors should consider how CEL-SCI Corporation fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
40.21M
P/E Ratio
-0.64
Beta
0.51
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 40.21M market capitalization
- Trading Volume: 118.11K shares traded today
- Price Range: 52-week range of $1.98 - $32.70
- Exchange: Listed on New York Stock Exchange Arca
Financial Metrics
Market Analysis for CEL-SCI Corporation
CEL-SCI Corporation (CVM) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 40.21M, the company represents a significant player in its market. The stock is currently trading at $5.85 with a negativedaily change of 15.56%.
The company's 43 employee base and presence on the New York Stock Exchange Arcaexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.64, beta of 0.51, and 52-week price range from $1.98 to $32.70when evaluating investment opportunities.
Why Invest in CEL-SCI Corporation?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange Arca)
- • Experienced leadership under Geert R. Kersten
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.